Outlook Therapeutics, Inc. (OTLK): Operating Cash Flow
-$51.83M
Year ended 2025-09-30
-$56.15M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | -$51.83M | n/m | 2025-12-19, From 2024-10-01 |
| 2024-09-30 | -$68.79M | n/m | 2025-12-19, From 2023-10-01 |
| 2023-09-30 | -$42.97M | n/m | 2024-12-27, From 2022-10-01 |
| 2022-09-30 | -$56.67M | n/m | 2023-12-22, From 2021-10-01 |
| 2021-09-30 | -$54.25M | n/m | 2022-12-29, From 2020-10-01 |
| 2020-09-30 | -$31.79M | n/m | 2021-12-23, From 2019-10-01 |
| 2019-09-30 | -$32.29M | n/m | 2020-12-23, From 2018-10-01 |
| 2018-09-30 | -$33.04M | n/m | 2019-12-19, From 2017-10-01 |
| 2017-09-30 | -$15.51M | n/m | 2018-12-18, From 2016-10-01 |
| 2016-09-30 | -$45.48M | n/m | 2017-12-29, From 2015-10-01 |
| 2015-09-30 | -$27.48M | n/a | 2016-12-29, From 2014-10-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$51.83M | n/m |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | -$6.03M | n/m |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | -$129.79M | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | -$19.59M | n/m |
| Humacyte, Inc. (HUMA) | 2025-12-31 | -$105.04M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | -$82.50M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$120.12M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$47.84M | n/m |
| Dyadic International Inc (DYAI) | 2025-12-31 | -$5.70M | n/m |
Compare OTLK, SCNI, INBX, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗